 |
Indication & Dosage |
| |
| |
| Vaginal |
| CERVICAL PRIMING, INDUCTION AND AUGMENTATION OF LABOUR |
| Adult:
As cervical gel: Apply 500 mcg in 2.5 mL preparation. May be repeated after 6 hr if necessary. |
| Max Dosage: 1.5 mg/24 hr. |
| |
| Oral |
| INDUCTION OF LABOR |
| Adult:
As vaginal gel: 1 mg (or 2 mg for primigravid patients with unfavourable induction features) followed by another 1 or 2 mg after 6 hr if necessary. Max: 3 mg (or 4 mg in unfavourable primigravid patients). As pessary: Initially, 3 mg followed by a further 3 mg after 6-8 hr if necessary. |
| Max Dosage: 6 mg. |
| |
| Extra-amniotic |
| TERMINATION OF PREGNANCY 2ND TRIMESTER |
| Adult:
As 100 mcg/mL soln: Instill 1 mL through a suitable foley catheter followed by 1-2 mL at 2-hr intervals according to patient's response |
|
| |
|
| Precautions |
Raised intraocular pressure. Previous caesarean section; history of asthma, epilepsy, hepatic or renal dysfunction, cardiovascular disease; pregnancy. |
| |
|
Potentially Life-threatening
Adverse Drug Reactions |
Hypersensitivity reactions, nausea, vomiting, diarrhoea, abdominal pain; flushing, shivering, headache, dizziness; hypertension; convulsions, ECG changes,local tissue irritation, erythema; pyrexia, increased WBC. Uterine contractile abnormalities with or without foetal distress. Dosage >0.5 mg intracervically can cause hypertonic uterine contractions. Intra/extra-amniotic inj: Local infection, vomiting, diarrhoea, pyrexia, transient hypotension. |
| |
|
| Adverse Drug Reactions |
Sudden CV collapse due to accidental IV absorption and intra-amniotic inj. Uterine rupture, amniotic fluid embolism during labour. Foetal distress and death in rare cases. |
| |
|
|
|
